Status:

COMPLETED

Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT)

Lead Sponsor:

AstraZeneca

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Brief Summary

Patients are eligible for inclusion in this NIS if they have taken anastrozole either upfront or following two to three years of tamoxifen treatment ("switch") for at least three and not more than six...

Detailed Description

The patient population will include postmenopausal women with hormone-receptor positive primary breast cancer scheduled for adjuvant upfront endocrine treatment with anastrozole or following two to th...

Eligibility Criteria

Inclusion

  • Postmenopausal women aged 18 years or older; Postmenopause is defined as Natural menopause with menses \>1 year ago or Serum FSH (\> 20 IU/ l), and E2 levels in the postmenopausal range or patients who had bilateral oophorectomy
  • Histologically / cytologically confirmed primary diagnosis of early breast cancer (M0) with hormone sensitive tumour (ER+ve and/or PgR+ve)
  • Patients, who underwent breast cancer surgery and, if appl. radiation therapy and/or neo/adjuvant chemotherapy and have taken adjuvant endocrine treatment with anastrozole (upfront or following two to three years of tamoxifen) min 3 max 6 months
  • In case of a previous therapy with tamoxifen (switch-therapy), duration of tamoxifen treatment for at least two and up to three years.

Exclusion

  • Patients with severe renal function disorders (Creatinine clearance \< 20 ml/min or Patients with moderate or severe disorders of hepatic function
  • Concomitant treatment with drugs known to affect sex hormonal status and tamoxifen
  • Patients with ductal carcinoma in situ (DCIS) without primary diagnosis of early breast cancer (M0)
  • Evidence of any significant clinical disorder or laboratory finding which in the opinion of the investigator, makes it undesirable for the patient to participate in the program

Key Trial Info

Start Date :

April 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

February 1 2012

Estimated Enrollment :

2313 Patients enrolled

Trial Details

Trial ID

NCT00857012

Start Date

April 1 2009

End Date

February 1 2012

Last Update

November 12 2012

Active Locations (383)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 96 (383 locations)

1

Research Site

Aachen, Germany, Germany

2

Research Site

Aalen, Germany, Germany

3

Research Site

Ahaus, Germany, Germany

4

Research Site

Albstadt, Germany, Germany